Achondroplasia: Introduction

  • Achondroplasia is a genetic disorder characterized by underdevelopment of bones, particularly the long bones of the body leading to dwarfism. The word ‘achondroplasia’ literally means ‘without cartilage formation’. However, the problem with the condition is not with cartilage formation, but with conversion of cartilage to bones, a process called ossification. Achondroplasia is caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene that results in its protein being overactive. The disorder has an autosomal dominant mode of inheritance; meaning only one mutated copy of the gene is required for the condition to occur. Achondroplasia is also the most common form of dwarfism. The condition is known to affect 1 in 15,000 to 40,000 newborns.
  • Achondroplasia is characterized by short arms and legs, but typically a normal length torso. The average adult height of those affected ranges from 4 ft to 4.4 ft. Other common features include short arms and legs, average-size trunk, an enlarged head, and a prominent or protruding forehead. The complications or risk factors associated include breathing difficulties such as sleep apnea, obesity, spinal stenosis, and recurrent ear infections. The disorder does not generally affect intelligence.

 Request Brochure for Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76979

Key Drivers and Restraints of Global Achondroplasia Treatment Market

  • Currently, there is no cure or prevention for achondroplasia. However, growth hormone therapy and surgery is used to minimize the conditions and help the patient to have apparently normal growth and life. Other supportive treatments are used to treat or prevent complications such as obesity, hydrocephalus, obstructive sleep apnea, middle ear infections, or spinal stenosis.
  • Rise in awareness about timely diagnosis of congenital disorders is projected to propel the global achondroplasia treatment market during the forecast period. Rise in cases of achondroplasia results in increase in research & development by companies and research institutes in clinical trials to manufacture novel therapeutics. Increase in investment in research & development for the treatment and management of achondroplasia is expected to drive the global market during the forecast period.
  • However, poor reimbursement, lack of awareness, and short duration effectiveness of growth hormone therapy is anticipated to hamper market growth

 Request for Analysis of COVID19 Impact on Achondroplasia Treatment Market –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=76979

Supportive Therapy to Lead Global Market

  • The global achondroplasia treatment market can be segmented based on treatment type, end-user, and region
  • In terms of treatment type, the global achondroplasia treatment market can be divided into growth hormone therapy, surgery, and supportive therapy. Supportive therapy is projected to be the fastest growing segment of the global achondroplasia treatment market.
  • Based on end-user, the global achondroplasia treatment market can be classified into hospitals, specialty clinics, retail pharmacies, and others

Pre book Market Report –

https://www.transparencymarketresearch.com/checkout.php?rep_id=76979&ltype=S

Asia Pacific to be Lucrative Market

  • The global achondroplasia treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • Improving health care infrastructure, rise in awareness about timely diagnosis of underlying disorders, and large undiagnosed patient population are anticipated to present significant opportunities in the achondroplasia treatment market in Asia Pacific in the near future. Increase in public and private health care expenditure in countries such as China, India, and Brazil is expected to attract manufacturers toward these markets.

 Ask for Discount :

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=76979

Key Players Operating in Global Achondroplasia Treatment Market

Leading players in the global achondroplasia treatment market include:

  • Ascendis Pharma A/S
  • BioMarin Pharmaceutical, Inc.
  • Ribomic, Inc.

Browse More Reports by Transparency Market Research:
Peptide Therapeutics Market:
https://www.prnewswire.com/news-releases/high-prevalence-of-cancer-and-other-chronic-conditions-to-bode-well-for-the-peptide-therapeutics-market-however-steep-cost-of-new-therapeutic-development-could-stifle-market-growth-says-tmr-301266752.html
Implantable Cardiac Monitor Market:
https://www.prnewswire.com/news-releases/implantable-cardiac-monitor-market-to-thrive-on-increasing-incidence-of-cardiac-arrhythmias-technological-innovations-to-present-better-treatment-opportunities-for-geriatric-population-with-cardiac-conditions-tmr-301262941.html

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

LEAVE A REPLY

Please enter your comment!
Please enter your name here